Advertisement

Dose of Anti-VEGF Injection in Infants

  • Ulrich Spandau
  • Sang Jin Kim
Chapter

Abstract

This chapter is about the dose of anti-VEGF injection in infants. The most recent studies regarding the dose of bevacizumab (Avastin) and ranibizumab (Lucentis) for ROP are summarized.

Keywords

Dose Bevacizumab Avastin Ranibizumab Lucentis ROP 

References

  1. 1.
    Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.CrossRefGoogle Scholar
  2. 2.
    Laws DE, Haslett R, Ashby D, O’Brien C, Clark D. Axial length biometry in infants with retinopathy of prematurity. Eye (Lond). 1994;8:427–30.CrossRefGoogle Scholar
  3. 3.
    Kim J, Kim SJ, Chang YS, Park WS. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina. 2014;34:77–82.CrossRefGoogle Scholar
  4. 4.
    Yoon JM, Shin DH, Kim SJ, Ham DI, Kang SW, Chang YS, Park WS. Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I. Retina. 2017;37:88–96.CrossRefGoogle Scholar
  5. 5.
    Hillier RJ, Connor AJ, Shafiq AE. Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series. Br J Ophthalmol. 2018;102:260–4.CrossRefGoogle Scholar
  6. 6.
    Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, Rogers DL, Yang MB, Haider KM, VanderVeen DK, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Hartnett ME, Kong L, Holmes JM, Pediatric Eye Disease Investigator Group (PEDIG). Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135:654–6.CrossRefGoogle Scholar
  7. 7.
    Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, McGregor ML, Jordan CO, Mantagos IS, Bell EF, Kraker RT, Pediatric Eye Disease Investigator Group. A dosing Study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments. Ophthalmology. 2018;125:1961–6.  https://doi.org/10.1016/j.ophtha.2018.05.001.CrossRefPubMedGoogle Scholar
  8. 8.
    Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, Ehrt O, Aisenbrey S, Roider J, Gerding H, Jandeck C, Smith LEH, Walz JM, Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (CARE-ROP) Study Group. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 2018;172:278–86.CrossRefGoogle Scholar
  9. 9.
    Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179–82.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ulrich Spandau
    • 1
  • Sang Jin Kim
    • 2
  1. 1.OphthalmologyUniversity of Uppsala OphthalmologyUppsalaSweden
  2. 2.Department of OphthalmologySamsung Medical Center, Sungkyunkwan UniversitySeoulSouth Korea

Personalised recommendations